Skip Navigation


European Heart Journal Advance Access originally published online on June 7, 2006
European Heart Journal 2006 27(13):1513-1514; doi:10.1093/eurheartj/ehl007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/13/1513    most recent
ehl007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rajagopal, V.
Right arrow Articles by Bhatt, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajagopal, V.
Right arrow Articles by Bhatt, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Gaps in myocardial infarction care: how might we best EFFECT change?

Vivek Rajagopal and Deepak L. Bhatt*

Department of Cardiovascular Medicine/F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA

* Corresponding author: Tel: +1 216 445 4042; fax: +1 216 445 8531. E-mail address: bhattd@ccf.org

This editorial refers to ‘Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction’{dagger} by D.A. Alter et al., on page 1539

The first 10% of the full text of this article appears below.

Despite medical advances, coronary artery disease continues to burden us. Millions worldwide have a myocardial infarction each year, and millions suffer the ravages of atherosclerosis: stable and unstable angina, congestive heart failure, and sudden cardiac death. Combating this plague has always required attention to research—biology of atherosclerosis, drug development, clinical trials—and attention to implementation—access to care, guideline dissemination, and treatment standardization.

The story of ST-elevation myocardial infarction (STEMI) illustrates the difficulty of doing this. The science has been, in relative terms, easy. Investigators have steadily progressed from using aspirin to administering thrombolytics and to employing primary percutaneous intervention; these advances, along with adjunctive therapy such as beta-blockers . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction
David A. Alter, Dennis T. Ko, Alice Newman, and Jack V. Tu
EHJ 2006 27: 1539-1549. [Abstract] [Full Text]